Overview

Drug repurposing is the development of existing drugs for new uses: given that 9 in 10 drugs that enter drug development are never marketed and therefore represent wasted effort, it is an attractive as well as inherently more efficient process. Three repurposed drugs can be brought to market for the same cost as one new chemical entity; and they can also be identified more quickly, an important benefit for patients whose diseases are progressing faster than therapeutic innovation. But repurposing also requires a fresh look at configuring pharmaceutical R&D, considering clinical, regulatory and patent issues much earlier than would otherwise be the case; a holistic gedanken experiment almost needs to be undertaken at the very start of any repurposing development. In addition to new ways of thinking, the discovery of repurposing opportunities can take advantage of artificial intelligence techniques to match the perfect new use for an existing drug. And while repurposing of medicines has been in the mind of every doctor since Hypocrates, modern clinical practice will simply have to adapt to new repurposing techniques in an age where the number of known diseases is increasing much faster than the healthcare dollars available.

Full Product Details

Author:   David Cavalla (Numedicus, UK) ,  David Rubinsztein ,  Richard Wyse ,  Jane Escott
Publisher:   Royal Society of Chemistry
Imprint:   Royal Society of Chemistry
Volume:   Volume 82
Weight:   1.479kg
ISBN:  

9781788019033

ISBN 10:   1788019032
Pages:   350
Publication Date:   09 February 2022
Audience:   College/higher education ,  Professional and scholarly ,  Tertiary & Higher Education ,  Professional & Vocational
Format:   Hardback
Publisher's Status:   Active
Availability:   In Print  
This item will be ordered in for you from one of our suppliers. Upon receipt, we will promptly dispatch it out to you. For in store availability, please contact us.

Table of Contents

Introduction and Historical Overview of Drug Repurposing Opportunities; Role of Academia: Drug Repurposing to Induce Autophagy for Treatment of Neurodegenerative Diseases; The Role of Clinical Medicine; Role of Industry; Collaboration Models for Repurposing; Screening Technologies; Cheminformatics Data Mining and Modeling for Drug Repurposing; Using Artificial Intelligence for Drug Repurposing; Field Discoveries (Case Reports); Preclinical. A Repurposed Novel Lyn Kinase Activator, MLR-1023, is a Model Example of Pharmacological Pleiotropy; Harnessing the Potential of Early Access: Advancing Timely Patient Access to Innovative Medicines in a Sustainable Way; Adapting Payers’ and Producers’ Incentives to Drug Repurposing; Intellectual Property Considerations; Regulatory Considerations and Strategies for Drug Repositioning; Future Perspectives in Drug Repurposing

Reviews

Author Information

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions